Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease

Like other neurodegenerative diseases, Alzheimer Disease (AD) has a prominent inflammatory component mediated by brain microglia. Reducing microglial inflammation could potentially halt or at least slow the neurodegenerative process. A major challenge in the development of treatments targeting brain inflammation is the sheer complexity of the molecular mechanisms that determine whether microglia become inflammatory or take on a more neuroprotective phenotype. The process is highly multifactorial, raising the possibility that a multi-target/multi-drug strategy could be more effective than conventional monotherapy. This study takes a computational approach in finding combinations of approved drugs that are potentially more effective than single drugs in reducing microglial inflammation in AD. This novel approach exploits the distinct advantages of two different computer programming languages, one imperative and the other declarative. Existing programs written in both languages implement the same model of microglial behavior, and the input/output relationships of both programs agree with each other and with data on microglia over an extensive test battery. Here the imperative program is used efficiently to screen the model for the most efficacious combinations of 10 drugs, while the declarative program is used to analyze in detail the mechanisms of action of the most efficacious combinations. Of the 1024 possible drug combinations, the simulated screen identifies only 7 that are able to move simulated microglia at least 50% of the way from a neurotoxic to a neuroprotective phenotype. Subsequent analysis shows that of the 7 most efficacious combinations, 2 stand out as superior both in strength and reliability. The model offers many experimentally testable and therapeutically relevant predictions concerning effective drug combinations and their mechanisms of action.

[1]  R. Campbell Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus , 1998, The Annals of pharmacotherapy.

[2]  K. Jeon,et al.  Thiol-Reactive Metal Compounds Inhibit NF-κB Activation by Blocking IκB Kinase1 , 2000, The Journal of Immunology.

[3]  R. Ransohoff,et al.  CX 3 CR 1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer ’ s Disease Mouse Models , 2010 .

[4]  J. Johansson Amyloid fibrils , 2005, The FEBS journal.

[5]  M. Citron,et al.  Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.

[6]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[7]  R. Armstrong A critical analysis of the 'amyloid cascade hypothesis'. , 2014, Folia neuropathologica.

[8]  M. Schwartz,et al.  Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. , 2005, Molecular and cellular neurosciences.

[9]  S. Allan,et al.  Assessing the contribution of inflammation in models of Alzheimer's disease. , 2011, Biochemical Society transactions.

[10]  P. Sanberg,et al.  Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. , 2004, Journal of neurochemistry.

[11]  M. Lynch,et al.  Neuroinflammatory changes increase the impact of stressors on neuronal function. , 2009, Biochemical Society transactions.

[12]  Seung-Up Kim,et al.  Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar β amyloid peptide (1-42)-stimulated microglia , 2008, Experimental & Molecular Medicine.

[13]  H. Kettenmann,et al.  Physiology of microglia. , 2011, Physiological reviews.

[14]  Mark Ryan,et al.  Logic in Computer Science: Modelling and Reasoning about Systems , 2000 .

[15]  David D. Smith,et al.  Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells , 2007, Molecular Cancer Therapeutics.

[16]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[17]  M. Schwartz,et al.  Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective , 2005, Molecular and Cellular Neuroscience.

[18]  J. Koenigsknecht-Talboo,et al.  Fibrillar β-Amyloid-stimulated Intracellular Signaling Cascades Require Vav for Induction of Respiratory Burst and Phagocytosis in Monocytes and Microglia* , 2006, Journal of Biological Chemistry.

[19]  T. Anastasio,et al.  Temporal-logic analysis of microglial phenotypic conversion with exposure to amyloid-β. , 2015, Molecular bioSystems.

[20]  V. Perry,et al.  Microglial physiology: unique stimuli, specialized responses. , 2009, Annual review of immunology.

[21]  M. Hopp,et al.  Low absolute bioavailability of oral naloxone in healthy subjects. , 2012, International journal of clinical pharmacology and therapeutics.

[22]  I. Torres-Aleman,et al.  The many faces of insulin-like peptide signalling in the brain , 2012, Nature Reviews Neuroscience.

[23]  P. Bosco,et al.  Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection , 2011, Cell and Tissue Research.

[24]  J. Miklossy,et al.  Chronic inflammation and amyloidogenesis in Alzheimer's disease -- role of Spirochetes. , 2008, Journal of Alzheimer's disease : JAD.

[25]  George Perry,et al.  Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. , 2009, Journal of Alzheimer's disease : JAD.

[26]  R. Mrak,et al.  Interleukin‐1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease , 2002, Journal of leukocyte biology.

[27]  J. Trojanowski,et al.  Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. , 2004, The American journal of pathology.

[28]  M. Lynch,et al.  Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain , 2009, Neurobiology of Aging.

[29]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[30]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[31]  R. Bernhardi Glial cell dysregulation: a new perspective on Alzheimer disease , 2007, Neurotoxicity Research.

[32]  Mark R Hutchinson,et al.  (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. , 2012, The journal of pain : official journal of the American Pain Society.

[33]  C. Reitz Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review , 2012, International journal of Alzheimer's disease.

[34]  T. Henzinger,et al.  Executable cell biology , 2007, Nature Biotechnology.

[35]  Sarah L. Kinnings,et al.  Novel computational approaches to polypharmacology as a means to define responses to individual drugs. , 2012, Annual review of pharmacology and toxicology.

[36]  Steffen Jung,et al.  Control of microglial neurotoxicity by the fractalkine receptor , 2006, Nature Neuroscience.

[37]  Dae-Myung Jue,et al.  Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit , 2003, Experimental & Molecular Medicine.

[38]  B. Necela,et al.  Toll‐like receptor 4 mediates cross‐talk between peroxisome proliferator‐activated receptor γ and nuclear factor‐κB in macrophages , 2008, Immunology.

[39]  K. Takeda [Toll-like receptor]. , 2005, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[40]  G. Landreth,et al.  CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation , 2009, The Journal of Neuroscience.

[41]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[42]  J. Laubach,et al.  New Proteasome Inhibitors in Myeloma , 2012, Current Hematologic Malignancy Reports.

[43]  S James Matthews,et al.  Thalidomide: a review of approved and investigational uses. , 2003, Clinical therapeutics.

[44]  R. Ransohoff,et al.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. , 2010, The American journal of pathology.

[45]  F. Hassan,et al.  Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-α production via down-regulation of MyD88 expression , 2009, Innate immunity.

[46]  G. Landreth,et al.  Identification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of β-Amyloid and Prion Proteins , 1999, The Journal of Neuroscience.

[47]  L. Ivashkiv,et al.  Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. , 2012, Arthritis and rheumatism.

[48]  G. Landreth,et al.  Microglia and inflammation in Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.

[49]  N. Andreasen,et al.  Pathways to Alzheimer's disease , 2014, Journal of internal medicine.

[50]  S. Verstovsek Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis , 2013, Postgraduate medicine.

[51]  Long Wang,et al.  Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials , 2014, Leukemia & lymphoma.

[52]  A. Cuello,et al.  Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease , 2014, Neurobiology of Aging.

[53]  M. A. Ajmone-Cat,et al.  Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures , 2005, Journal of Neuroinflammation.

[54]  R. von Bernhardi Glial cell dysregulation: a new perspective on Alzheimer disease. , 2007, Neurotoxicity research.

[55]  S. Maier,et al.  Non‐stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll‐like receptor 4 (TLR4) , 2008, The European journal of neuroscience.

[56]  J. Koenigsknecht-Talboo,et al.  Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.

[57]  Mohammad A Kamal,et al.  Link between chronic bacterial inflammation and Alzheimer disease. , 2014, CNS & neurological disorders drug targets.

[58]  W. Wong Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation , 2013, Front. Cell. Neurosci..

[59]  Hayyoung Lee,et al.  The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.

[60]  S. Skaper Alzheimer's disease and amyloid: culprit or coincidence? , 2012, International review of neurobiology.

[61]  Mark S. Shearman,et al.  Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .

[62]  Narciso Martí-Oliet,et al.  All About Maude - A High-Performance Logical Framework, How to Specify, Program and Verify Systems in Rewriting Logic , 2007, All About Maude.

[63]  D. Jue,et al.  Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. , 2003, Experimental and Molecular Medicine.

[64]  Hyoung-Gon Lee,et al.  Challenging the Amyloid Cascade Hypothesis: Senile Plaques and Amyloid‐β as Protective Adaptations to Alzheimer Disease , 2004, Annals of the New York Academy of Sciences.

[65]  V. Ingham,et al.  Glimepiride reduces CD14 expression and cytokine secretion from macrophages , 2014, Journal of Neuroinflammation.

[66]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[67]  K. Jeon,et al.  Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. , 2000, Journal of immunology.

[68]  Douglas R. McDonald,et al.  Amyloid Fibrils Activate Tyrosine Kinase-Dependent Signaling and Superoxide Production in Microglia , 1997, The Journal of Neuroscience.

[69]  G. Jansen,et al.  Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. , 2012, Blood.